Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607733 | 0.83 | LMNA (0.52) | KMT2AMEN1PDE7ALMNASMN1; SMN2 | |
| SCHEMBL2821186 | 0.82 | HPSE (0.56) | KMT2AMEN1PDE7AEPAS1LMNA | |
| SCHEMBL2821818 | 0.81 | LMNA (0.67) | KMT2AMEN1PDE7AEPAS1LMNA | |
| SCHEMBL4398948 | 0.79 | ALDH1A1 (0.57) | KMT2AMEN1LMNASMN1; SMN2POLB | |
| SCHEMBL2678638 | 0.78 | LMNA (0.51) | KMT2AMEN1PDE7AEPAS1LMNA | |
| SCHEMBL2678631 | 0.78 | LMNA (0.51) | KMT2AMEN1PDE7AEPAS1LMNA | |
| SCHEMBL5607423 | 0.78 | MAPT (0.45) | KMT2AMEN1LMNASMN1; SMN2POLB | |
| SCHEMBL4402565 | 0.77 | VCAM1 (0.63) | KMT2AMEN1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL641210 | 0.72 | HPGD (0.63) | KMT2AMEN1PDE7AEPAS1LMNA | |
| SCHEMBL2826350 | 0.71 | MERTK (0.60) | KMT2AMEN1PDE7AEPAS1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8175860-B2 | Method of inhibiting the growth of Helicobacter pylori | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-05-08 | — | — | US | disclosed |
| US-20100305152-A1 | METHOD OF INHIBITING THE GROWTH OF HELICOBACTER PYLORI | NATIONAL TSING HUA UNIVERSITY (TW) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305152-A1 | METHOD OF INHIBITING THE GROWTH OF HELICOBACTER PYLORI | HPD, HAAO, HK1 | KMT2A 2315/4885MEN1 2935/4885PDE7A 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.